Tackling both transactions and disputes in the life sciences sector, Gibson, Dunn & Crutcher LLP is sought out by clients engaged in Hatch-Waxman and product liability litigation, in addition to those both seeking financing or seeing through M&A. Taking the lead on corporate and transactional matters is Ryan Murr, who counsels pharmaceutical, biotech and diagnostics companies on business combinations and securities transactions out of San Francisco, while New York-based Jane Love spearheads the practice’s efforts on the IP front, where she represents clients in litigation concerning biologics and small molecule therapies.
Legal 500 Editorial commentary
Accolades
Client satisfaction
Key clients
- Guardant Health
- Gilead Sciences
- Dental Monitoring SAS
- Merck & Co., Inc.
- Cullgen Inc.
- GE Healthcare
- CTI BioPharma Inc.
- Elliott Investment Management L.P.
- Heska Corporation
- Tenet Healthcare Corporation
Work highlights
- Advised Elliott Investment Management on the $7.1bn acquisition by a private investment consortium of Syneos Health.
- Advised Cullgen on a $1.9bn strategic collaboration and option agreement to advance innovative targeted protein degraders with Astellas Pharma.
- Advised Merck on its $1.35bn acquisition of Imago BioSciences, Inc.
Lawyers
Practice head
Ryan Murr; Jane Love
Other key lawyers
Branden Berns; Charlotte Jacobsen; Karen Spindler; Todd Trattner